Skip to main content
Healthcare

STAT+: PepGen says early trial for muscular dystrophy drug looks promising

STAT+: PepGen says early trial for muscular dystrophy drug looks promising

Feed excerpt — reported by STAT News

Biotech says its candidate is correcting more of the genetic stutter found in myotonic dystrophy type 1.

MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at STAT News →

Original Source

This article was syndicated from STAT News. All rights remain with the original publisher.